1935
 
 - The Company was Incorporated at Mumbai.
 
 1979
 
 - The Company acquired a plot of land from MIDC at Patalganga in
 Kulaba
 district of Maharashtra State about 55 kms. from Mumbai.
 
 - 18,773 Bonus equity shares issued in proportion 1:1.
 
 1984
 
 - The name of the Company was changed from The Chemical Industrial &
 Pharmaceutical Laboratories Ltd., to the present one with effect
 from
 20th July.
 
 1985
 
 - 37,546 Bonus equity shares issued in proportion 1:1 in January
 1986.
 
 1986
 
 - During August, the Company obtained the consent of the Controller
 of
 Capital Issues to issue 3,00,000-15% secured non-convertible
 redeemable
 debentures of Rs 100 each aggregating to Rs 300 lakhs by private
 placement.  The entire issue was subscribed by public financial
 institutions.  They are redeemable at a premium of 5% during
 1993-94.
 
 1987
 
 - The Company launched several new products viz., Asthalin and
 Beclate
 Rotahalers/Rotacaps-dry powder inhalation devices for asthma,
 presolar
 capsules - the first synergistic combination of a beta blocker and a
 sustained release calcium channel blocker for hypertension, Restyl
 tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR
 tablets - the first sustained release combination of two widely used
 bronchodilators, bromolin dry syrup and bromolin-250 capsules -
 antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium
 channel blocker for angina, ibugesic plus suspension - a non
 steroidal
 anti inflammatory and anti-pyretic analgesic for paediatric use.
 
 - 75,092 Bonus equity shares issued in proportion 1:1.
 
 1989
 
 - The latest drugs introduced during the year were (i) Ciplox
 tablets
 (250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum
 fluoroquinolone antibacterial for severe infections, (ii) cefadur
 capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin
 antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2
 antogonist for peptic ulcers and (iv) theoped syrup, a paediatric
 bronchodilator.  Sales in the Company's `PROTEC' division exceeded
 Rs
 5.50 crores for the second year of its operations.
 
 1990
 
 - The Company launched several new products viz., Aerocort inhaler,
 an
 anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad
 spectrum fluoroquinolone antibacterial, Pirox Gel - the first
 topical
 piroxicam formulation in the country, Cofenac tablets - an
 anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional
 drug for vascular insufficiency, Novaclox Ped tablets - a
 dispensible
 combination antibiotics, Terfed tablets and Suspension - a new
 non-sedative antihistamine, Depryl tablets - a broad - spectrum
 antidepressant, Asthalin Respirator Solution - a bronchodilator for
 pressure ventilation in acute asthma.  The Company spent Rs 4.22
 crores
 on R&D and Rs 8.09 crores on modernisation and expansion of plant
 and
 machinery.
 
 1991
 
 - The new products launched during the year were lomac capsules - a
 new
 antiulcerant, cromal inhaler - the first optimum - dose inhalant
 prophylactic for asthma, ciplox eye drops - the total bactericide
 for
 ocular infections, etosid injection - the first injection of
 indigenously manufactured etoposide for cancer therapy, proflox
 tablets
 - a key fluoroquinolone antibiotic and vasopril tablets - an ACE
 inhibitor for long-term management of hypertension.  The research
 and
 development wing of the Company developed during the y ar felodipine
 -
 the latest anti-hypertensive drug, selegilinje - a new bulk drug for
 the treatment of Parkinson's disease, cetirizine HCI - an
 anti-histamine drug and nimodipine - a cerebral vasodilator.  Work
 on
 the anti-AIDS drug AZT reached an advance stage of development.  The
 research and development wing also developed anthelmintics
 oxfendazole
 and oribendazole, two veterinary products for exports.
 
 - In May, 6,000 equity shares offered at par as rights to pref.
 shareholders in prop. 1:1.  Only 5,216 shares taken up.  Allotment of
 5
 equity shares pending.
 
 1992
 
 - Some of the new products introduded were Zidovir capsules an
 antiretroviral for HIV injection, Cipril tablets for hypertension,
 Optipres eyedrops for glaucoma patients, Felogard for hypertension,
 Nodine, a non-narcotic analgesic, etc.
 
 - In compliance with the provisions of the Companies Act, 1956, the
 Company redeemed its 6,000 preference shares of Rs 100 each as on
 30th
 September.
 
 - Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares
 issued
 in prop. 1:1.
 
 1994
 
 - New products introduced were - Beclate Aquanase - a major
 advancement
 in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an
 antifungal; Imusporin - an immunosuppressant in organ
 transplantation;
 Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump
 inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic
 and Qinarsol - for chloroquin-resistant malaria.
 
 - Equity shares subdivided 155,39,500.  Equity shares allotted
 shares
 issued in prop. 1:5.
 
 - The Company's manufacturing unit at Kurkumbh, which was
 commissioned
 in April.  The second phase of expansion of the location was under
 way
 and this was to provide specialised facilities for the manufacture
 of
 new chemical entites.
 
 1995
 
 - Effective 4th July, the Company was forced to declare a lock-out
 as
 some of the workmen at the Vikhroli Unit resorted to indiscipline. 
 The
 Company initiated steps to mitigate the impact it could have on
 production.
 
 - New products introduced were - Acivir - antivirus herpes, Anlopres
 -
 antivirus herpes, Anlopres - Calcium channel blocker in hypertension
 and angina, Anlopres AT - a combination antihypertensive, Budecort
 200
 - a higher strength corticosterord in bronchial asthma, Budenase AQ -
 a
 corticosteroid protection in allergic rhinitis, cronal - a nast cell
 stabiliser in allergic conjunctivitis, cytonid - a antiandrogenic
 agent
 in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of
 mixed
 origin, optipes S - betaxocol eye drops, profenac -
 anti-inflammatory
 eye drops, Terfed D - a combination antihistamine and decongestant,
 Trivedon 20 - used in ischaemic heart disease.
 
 - A new chemical entity, candocuronium iodide - a neuromuscular
 blocking agent was manufactured, other new bulk drugs manufactured
 include: Acyelovir - antiviral, Amlodipine besylate -
 antihypertensive
 and antianginal, Febantel - veterinary anthelmintic, Flutamide -
 antiandrogen, Flutivcasone dipropionate - a corticosteriod,
 zenprolide
 acetate - GMRH analogue.
 
 - 13,43,383 rights equity shares issued (Prem. Rs. 60/-).  However,
 the
 Rights issue was underwritten.
 
 1996
 
 - The products launched during the year were Azee (azithromycin
 capsules) - a new macrolide antibiotic; Budecort (budesonide
 rotacaps)
 - dry powder inhaled corticosteriod therapy for asthama; Cipril H
 (lisionopril + hydrochlorothiazide tablets) - a combination
 antihypertensive; Ciplox TZ (ciprofloxacin + tinidazole tablets) -
 the
 combination bactericide for aerobic/anaerobic infections; Entosec
 (secnidazole tablets) - single dose therapy for
 amoebiasis/trichomoniasis; Fincar (finasterid tablets) - for beign
 prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker
 protection for post myocardial infarction & Zoflut (fluticasone
 propionate cream) - a new topical corticosteroid.
 
 1997
 
 - The products introduced during the year were; Alerid-D - an
 antihistamine and decongestant for cold and congestion, Amlopres L -
 a
 tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a
 single
 dose for STDs, Budecort Respules - neubulised corticosteroid therapy
 for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese
 diabetics, Glygard - tablet for abese diabetics, Glygard - tablet
 for
 diabetics, Ipranase AQ (ipratropium nasal spray) - an
 anticholinergic
 therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy
 in
 acquafilm formulation, Osteifos 10 - tablet for osteoporosis,
 Prolyte
 Fizz - a rehydration effervescent tablet, Pylokit - an advanced H
 pylori kit, Risnia - an a typical antipsychotic, Stavir - an
 antiretroviral for AIDS, Synclar 250 - an advanced macrolide
 antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical
 corticosteroid.
 
 - The bulk division of the Company had taken up, the development and
 manufacture of some new drugs viz., budesonide - antiasthmatic
 corticosteroid, carvedilol - alpha/beta blocker, ebastine -
 antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for
 osteroarthritis and rheumatoid arthritis, moclobemide -
 antidepressant,
 mometasome furoate - antiflammatory corticosteroid, pantorazole
 sodium
 sesquihydrate - antiulcerant, sildenafil citrate - erectile
 dysfuncion.
 
 - The Company has developed a form-fill-seal equipment for the first
 time in India, for the manufacture of sterile formulations.  This
 was
 commissioned at Vikhroli factory and is working to its full
 capacity.
 Additional capacities were set up at Kurkumbh for manufacture of
 effervescent tablets, soft gel capsules and injectable formulations.
 The Company has incurred a capital expenditure of Rs 22.73 crores
 during the year.
 
 - The Rs. 3.69 billion Cipla has finalised a marketing joint venture
 with Australia-based Genpharm, as part of its strategy to
 consolidate
 its global presence.
 
 - Pharmaceutical major Cipla Ltd grabbed the attention of traders at
 the Mumbai Stock Exchange (BSE) on December 26 after a large block
 of
 about 75,000 shares of the company valued at little over Rs 5 crore
 changed hands.
 
 - The Rs.369-crore Cipla Ltd has entered into a souring arrangement
 with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of
 Swiss multinational Ciba, for a range of generic drugs.
 
 1998
 
 - Pharmaceutical companies, Cipla and Wockhardt, will be seeking
 shareholders' approval for a proposed share buyback at their
 forthcoming annual general meetings.
 
 - In a notice to shareholders, Cipla has proposed introduction of a
 new
 article, Article 64 A, in the Articles of Association of the company
 to
 enable the company to purchase and re-issue any of its shares.  The
 existing Article 64 prohibits the company from buying its own shares
 and applying any of its funds for the purchase of any shares of the
 company.
 
 - The share price of Cipla Ltd, the leading pharmaceutical company
 scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29
 following fresh bull charge.  The scrip opened at Rs 900 and shot up
 to
 Rs 920 during mid-session and closed at Rs 884 following hectic
 trading
 activities.
 
 1999
 
 - Ranbaxy and Cipla, have entered into a strategic partnership to
 jointly market a select basket of drugs.  The alliance will bring
 forth
 their strengths in the strongly emerging cardiovascular and
 perennial
 anti-infectives market.
 
 - As a first step, the two molecules being jointly launched are
 Carvedilol, a new generation anti-hypertensive and Cefpodoxime
 Proxetil, an advanced third generation oral cephalosporin.
 
 - The Rs 541-crore Cipla has forged a strategic alliance with the
 UK-based Neolab for marketing a range of generic drugs.  The
 alliance,
 while improving the Indian company's access to the multi-billion
 dollar
 European market for off-patent drugs, will also see Cipla rake in
 royalties on sales of products covered under the deal.
 	 
 - Cipla's latest tie-up in the international market comes close on
 the
 heels of the company's strategic partnership with the Delhi-based
 Ranbaxy Laboratories for a select basket of drugs.
 	 
 - The Mumbai-based Cipla is working on abbreviated new drug
 applications (ANDAs) in collaboration with international generics
 firms
 for a range of products like flutamide (for advanced prostatic
 cancer)
 and felodipine, for hypertension.
 
 2000
 
 - Cipla and Ranbaxy Laboratories have expanded an existing
 partnership
 by adding one more new drug in their co-marketing arrangement.
 
 2001
 
 - Cipla has tied up with the US-based Zenith Goldline and United
 Research Labs for marketing Flutamide, an oncology drug, and
 Felodipine, a cardiovascular drug, in the US and European markets.
 
 - Domestic pharma giant, Cipla, has despatched its first free
 consignment of anti-AIDS drug, ‘Nevirapine’, to the Indian
 Government
 for distribution under the public health system.
 
 2002
 
 -Reduces the price of its anti-HIV medicines such as Stavir, Lamivir,
 Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir
 
 -Revokes interim dividend of Rs 5 per share on face value of Rs 10
 per share for FY 2001-02
 
 -Company included in the World Health Organisation's (WHO's) list of
 HIV-related products
 
 -Chairman and Managing Director YK Hamied was presented with the
 lifetime contribution award for excellence in the pharmaceutical
 industry by Union chemicals & fertilisers minister SS Dhindsa
 
 -Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill
 
 2003
 
 -Applies its requisiton for Abbreviated New Drug Application (ANDA)
 with US regulators for a post-menopausal drug
 
 -National Pharmaceutical Pricing Authority (NPPA) issues notices to
 Cipla along with Ranbaxy for overcharging the products
 
 -Completes research studies on three Anti-HIV Drugs
 
 -Registers Stavudine, Nevirapine, other anti-AIDS products in South
 Africa
 
 2004
 
 -Signs long-term agreement with Morton Grove Pharmaceuticals Inc
 (MGP) of Illinois, US, for product launch in the US market
 
 -Avesthagen forges alliance with Cipla
 
 -Cipla has joined a global initiative taken up by the Vatican in
 collaboration with global generic pharmaceutical manufacturers and
 the International Federation of Catholic Pharmacies and Academics to
 float CUMVIVIUM
 
 -Cipla join hands with Pentech Pharma
 
 -Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS
 drugs in Africa, has patented its three-in-one combination tablet
 Triomune in South Africa
 
 -Cipla introduces 'Duova' to fight chronic obstructive pulmonary
 disease
 
 - Launches a new treatment for arthritis in technical collaboration
 with California-based Cymbiotics Inc.
 
 2005
 -Set-up state-of-the-art facility for manufacture of formulations at
 Baddi, Himachal Pradesh.
 -Cipla introduces new drug for arthritis
 
 -Cipla to sign deal with Akorn Inc for anti-infective drug
 
 -Cipla to produce generic versin of bird-flu drug
 
 -Cipla to join hands with Roche
 
 - Cipla introduces new drug for arthritis
 
 2006
 
 - Cipla receives Scrip Award for Best Company in an Emerging Market 
 -Safe & steady strategy gives Cipla lead over Ranbaxy
 -Cipla sets up subsidiary in Dubai 
 -Cipla ties up with Ivax for US market 
 -Cipla receives tentative US FDA approval for AIDS drugs
 -Cipla receives Pharma Excellence Award for 'Sustained Growth' 
 
 
 2007
 
 - Cipla unveils anti-malaria global initiative.
 
 -Set-up state-of-the-art facility for manufacture of formulations at
 Sikkim.
 -Award for the Forbes Asia's “Best Under A Billion” List!
 -Cipla’s drug included in US anti-AIDS initiative 
 -Anti-AIDS blitz sees pharma firms locked in ugly battle 
 -Cipla launches emergency contraception tablet 
 -Cipla launches estradiol transdermal spray in India 
 -Cipla launches cut-price zanamivir in India 
 -Cipla receives International Trade Awards 2006 for outstanding
 exporter of the year (Pharmaceuticals, Healthcare and Life Sciences
 category) 
 2008
 
 -Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual
 vacancy with effect from 
 March 05, 2008.
 
 -Cipla launched Roche's generic version of anti-infection drug
 
 2009
 
 -Cipla wins Erlotinib case against Roche 
 -Pharmaceuticals Export Promotion Council Awards 
 -Cipla launches drug to treat Swine flu virus